Ana Cayuela López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Cayuela López has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Adolfo de la Lama Zaragoza
23 shared publicationsAlejandra Londoño Quiroz
23 shared publications- Alejandro Antón-Fernández
Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Nicolás Cabrera, 1, Cantoblanco, Madrid 28049, Spain
23 shared publications - Amanda Sierra
Achucarro Basque Center for Neuroscience
23 shared publications Ana González Piñeiro
23 shared publications- Ana de Pablos-Aragoneses
Spanish National Cancer Research Centre New York, NY United States
23 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S4. Dynamics of omentum macrophage and monocytic populations during peritoneal CRC tumor growth.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S4. Dynamics of omentum macrophage and monocytic populations during peritoneal CRC tumor growth.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Accumulating evidence indicates that peritoneal macrophages, comprising resident peritoneal macrophages (resMØ) and monocyte-derived nonresident macrophages (moMØ), contribute to peritoneal tumor progression by promoting tumor cell proliferation and migration and driving immunosuppression. However, the mechanisms governing the expansion of resMØs and moMØs, as well as their differential contributions to the peritoneal macrophage pool in tumor-bearing mice and to tumor growth, remain to be elucidated. Using a mouse model of colorectal cancer peritoneal metastasis, induced by intraperitoneal injection of tumor organoids derived from primary tumors in genetically engineered mice carrying Apc, Kras, Tgfbr2, and Trp53 mutations, and recapitulating human-like metastatic colorectal cancer, we investigated the origin, expansion, and function of peritoneal macrophages during metastatic tumor growth. Our data support that the low inflammatory status of the peritoneal cavity during colorectal cancer peritoneal tumor growth restrains monocyte recruitment and the differentiation of Tim4− resMØs and moMØs while enabling a marked, proliferation-driven expansion of Tim4+ resMØs. Tumor-induced Tim4+ resMØs displayed a migratory and protumor transcriptomic signature characterized by the activation of genes encoding key protumorigenic molecules and potential immunotherapeutic targets, including Adora2a/Adora2b, Arg1, Ido2, Acod1, Mmp12, Cd274, Pdcd1lg2, Spp1, Trem1, and Vegfa. Correspondingly, during peritoneal colorectal cancer tumor growth, Tim4+TREM1+ resMØs migrated to the omentum, the principal peritoneal target organ for metastasis, and promoted colorectal cancer peritoneal tumor progression. These findings may help lead to the development of immunotherapies for colorectal cancer peritoneal metastasis that target tumor-associated peritoneal macrophages.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Accumulating evidence indicates that peritoneal macrophages, comprising resident peritoneal macrophages (resMØ) and monocyte-derived nonresident macrophages (moMØ), contribute to peritoneal tumor progression by promoting tumor cell proliferation and migration and driving immunosuppression. However, the mechanisms governing the expansion of resMØs and moMØs, as well as their differential contributions to the peritoneal macrophage pool in tumor-bearing mice and to tumor growth, remain to be elucidated. Using a mouse model of colorectal cancer peritoneal metastasis, induced by intraperitoneal injection of tumor organoids derived from primary tumors in genetically engineered mice carrying Apc, Kras, Tgfbr2, and Trp53 mutations, and recapitulating human-like metastatic colorectal cancer, we investigated the origin, expansion, and function of peritoneal macrophages during metastatic tumor growth. Our data support that the low inflammatory status of the peritoneal cavity during colorectal cancer peritoneal tumor growth restrains monocyte recruitment and the differentiation of Tim4− resMØs and moMØs while enabling a marked, proliferation-driven expansion of Tim4+ resMØs. Tumor-induced Tim4+ resMØs displayed a migratory and protumor transcriptomic signature characterized by the activation of genes encoding key protumorigenic molecules and potential immunotherapeutic targets, including Adora2a/Adora2b, Arg1, Ido2, Acod1, Mmp12, Cd274, Pdcd1lg2, Spp1, Trem1, and Vegfa. Correspondingly, during peritoneal colorectal cancer tumor growth, Tim4+TREM1+ resMØs migrated to the omentum, the principal peritoneal target organ for metastasis, and promoted colorectal cancer peritoneal tumor progression. These findings may help lead to the development of immunotherapies for colorectal cancer peritoneal metastasis that target tumor-associated peritoneal macrophages.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S1. CRC peritoneal tumor growth in the omentum and quantification of soluble factors in the peritoneal lavage after injection of PBS, m204 MTOs or E. coli.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S1. CRC peritoneal tumor growth in the omentum and quantification of soluble factors in the peritoneal lavage after injection of PBS, m204 MTOs or E. coli.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S5. Flow cytometry analyses of CFSE labeling in the peritoneal lavage and omentum.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Low Inflammation Correlates with Protumor Tim4+TREM1+ Resident Macrophage Expansion and Limited Monocyte-Derived Macrophage Differentiation during Peritoneal Colorectal Cancer
Figure S5. Flow cytometry analyses of CFSE labeling in the peritoneal lavage and omentum.